Partner Headlines - CPHD

  1. LinkedIn, TripAdvisor, Google: Top Manager's Ideas

    IBD
  2. Alexion Takes Off On Outlook

    IBD
  3. Three Medical Tech Names To Watch In Healthcare Space

    IBD
  4. Align Leads Three Top-Rated Medical Equipment Stocks

    IBD
  5. UPDATE: JMP Securities Initiates Coverage on Cepheid on Market ...

    Benzinga
  6. Five Medical Stocks Leaders Trade Near New Highs

    IBD
  7. ViroPharma Gets Bought Out; Medicines Clears Entry

    IBD
  8. UPDATE: ISI Group Downgrades Cepheid on Key Drivers Constraining ...

    Benzinga
  9. Benzinga's Top Downgrades

    Benzinga
  10. UPDATE: Bank of America Downgrades Cepheid on Fair Valuation

    Benzinga
  11. Benzinga's Top Downgrades

    Benzinga
  12. Cepheid Reports Xpert MTB/RIF Categorized 'Moderate Complexity' ...

    Benzinga
  13. Cepheid Announces Board of Directors Changes

    Benzinga
  14. Cepheid's Chlamydia and N. Gonorrhoeae Test Categorized 'Moderate ...

    Benzinga
  15. Medtech Stocks Moving As Conference Makes Waves

    IBD
  16. Medtech Stocks Moving As Conference Makes Waves

    IBD
  17. Cepheid Offers Update on Xpert Test Availability, Sees Q4 Sales ...

    Benzinga
  18. UPDATE: Piper Jaffray Downgrades Cepheid to Neutral, Lowers PT

    Benzinga
  19. Oppenheimer Holdings Reiterates Outperform Rating, $43 PT on ...

    Benzinga
  20. Canaccord Genuity Reiterates Buy Rating, $50 PT on Cepheid

    Benzinga
  21. Cantor Fitzgerald Reiterates Hold Rating, $38 PT on Cepheid

    Benzinga
  22. US Stock Futures Down Ahead Of Economic Data

    Benzinga
  23. Stocks To Watch For December 28, 2012

    Benzinga
  24. UPDATE: Cepheid Wins FDA Clearance for Xpert CT/NG

    Benzinga
  25. UPDATE: Bank of America Initiates Cepheid at Buy on Prospects, ...

    Benzinga
  26. Look At That Base: If You Can't Name It, Don't Buy It

    IBD
  27. UPDATE: Goldman Sachs Downgrades Cepheid to Neutral on Lack of ...

    Benzinga
  28. Benzinga's Top Downgrades

    Benzinga
  29. Benzinga's Top Upgrades

    Benzinga
  30. CEPHEID Reports Operating Results (10-Q)

    GuruFocus
  31. UPDATE: Cantor Fitzgerald Maintains Cepheid at Hold on Analyst ...

    Benzinga
  32. UPDATE: Canaccord Genuity Reiterates Cepheid at Buy with $50 ...

    Benzinga
  33. Goldman Sachs Reiterates Buy Rating, $46 PT on Cepheid

    Benzinga
  34. UPDATE: ISI Group Reduces PT to $30.50 on Cepheid Post Analyst ...

    Benzinga
  35. Benzinga Mid-Afternoon Market Update

    Benzinga
  36. Stock Futures Point to Higher Open with Yahoo (YHOO) and Hewlett-Packard ...

    MarketIntelligenceCenter
  37. Benzinga Mid-Day Market Update

    Benzinga
  38. Mid-Morning Market Update

    Benzinga
  39. UPDATE: ISI Group Reduces PT to $32.50 on Cepheid Following Negative ...

    Benzinga
  40. Benzinga's Top Initiations

    Benzinga
  41. A Peek Into The Market Before The Trading Starts

    Benzinga
  42. UPDATE: JP Morgan Initiates Cepheid at Overweight on Growth Outlook

    Benzinga
  43. Benzinga's Top Initiations

    Benzinga
  44. Technology Sector Wrap

    FoxBusiness
  45. Technology Sector Wrap

    FoxBusiness
  46. Technology Sector Wrap

    FoxBusiness
  47. Analyst Downgrades: Cepheid, Intuitive Surgical, and Travelzoo

    SchaeffersResearch
  48. Cepheid Down 20% on Weak Guidance

    Benzinga
  49. CEPHEID (CPHD) CEO John L Bishop sells 40,201 Shares

    GuruFocus
  50. CEPHEID (CPHD) CEO John L Bishop sells 25,000 Shares

    GuruFocus
  51. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 17,437 Shares

    GuruFocus
  52. A Peek Into The Market Before The Trading Starts

    Benzinga
  53. UPDATE: UBS Investment Research Upgrades Cepheid to Buy; Opportunistic ...

    Benzinga
  54. Benzinga's Top Downgrades With Color for May 14, 2012

    Benzinga
  55. UPDATE: GARP Research & Securities Downgrades Cepheid to Neutral; ...

    Benzinga
  56. Cepheid Earnings Miss Estimates; Stock Plummets

    IBD
  57. Cepheid Q1 Estimates Soft, But Outlook For Year Good

    IBD
  58. Zoll Deal, Intutive Surgical Lift Medical Equipment

    IBD
  59. Cepheid Stock Price Rises on Strong 2012 Sales Outlook

    IBD
  60. CEPHEID Reports Operating Results (10-K)

    GuruFocus
  61. CEPHEID (CPHD) EVP, CFO Andrew Miller sells 62,062 Shares

    GuruFocus
  62. CEPHEID (CPHD) CEO John L Bishop sells 6,887 Shares

    GuruFocus
  63. CEPHEID (CPHD) Executive VP, COO Humberto Reyes sells 133,957 ...

    GuruFocus
  64. Stocks Finish Week Split; Nasdaq, S&P 500 Higher

    IBD
  65. Stocks Stay Mixed; Under Armour Clears 50-Day

    IBD
  66. RBC Capital Upgrades Cepheid to Outperform

    Benzinga
  67. UPDATE: Credit Suisse Initiates Outperform, $40 Target on Cepheid

    Benzinga
  68. Analogic Earnings Preview: EPS Expected to Double

    Benzinga
Trading Center